Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102518
Status:
COMPLETED
Last Update Posted:
2012-08-31
First Post:
2005-01-29
Brief Title:
Aripiprazole Open-Label Safety and Tolerability Study
Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Study Overview
Official Title:
A Multi-Center Open-Label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole 2 Mg-30 mg in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder Manic or Mixed Episode With or Without Psychotic Features
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APEX 241
Brief Summary:
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia and child and adolescent patients with bipolar I disorder manic or mixed episode
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None